Stopped: Study was terminated due to the lack of operational capabilities of the sites to segregate participants as needed.
This is a Phase 1, open-label, 2-part study to evaluate the effect of multiple doses of oral carbamazepine or oral itraconazole on the plasma pharmacokinetic profile of radiprodil in healthy adult participants. In addition, the safety and tolerability of radiprodil given together with oral carbamazepine or itraconazole will be assessed.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: To assess the effect of oral carbamazepine on the maximum observed plasma concentration (Cmax) of oral dosing of radiprodil
Timeframe: Blood samples will be collected on Days 7 to 10 and 25 to 28.
Part B: To assess the effect of oral itraconazole on the maximum plasma concentration (Cmax) of oral dosing of radiprodil
Timeframe: Blood samples will be collected Days 5 to 9 and 18 to 22.
Part A: To asses the effect of oral carbamazepine on radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)
Timeframe: Blood samples will be collected on Days 7 to 10 and 25 to 28.
Part B: To asses the effect of oral itraconazole on the radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)
Timeframe: Blood samples will be collected Days 5 to 9 and 18 to 22.
Part A: To assess the effect of oral oral carbamazepine on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil
Timeframe: Blood samples will be collected on Days 7 to 10 and 25 to 28
Part B: To assess the effect of oral itraconazole on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodil
Timeframe: Blood samples will be collected Days 5 to 9 and 18 to 22